3 Reasons to Avoid NVST and 1 Stock to Buy Instead
This article advises investors to avoid Envista Holdings Corp (NVST) despite its recent stock performance. The author highlights three main reasons: disappointing long-term revenue growth, previous growth initiatives losing money due to negative ROIC, and a decline in new investment returns. Instead, the article suggests looking into the most entrenched endpoint security platform on the market and provides a link to "Top 6 Stocks" list.
Envista Stock Rises Post Q4 Earnings & Revenue Beat, Gross Margin Down
Envista Holdings Corporation (NVST) reported strong Q4 2025 results, with adjusted EPS up 58.3% year over year and revenues increasing by 15%, both beating Zacks Consensus Estimates. Despite a contraction in gross margin, the company's operational profit significantly improved, and its shares rallied post-announcement. Envista remains optimistic about its core sales growth and adjusted EBITDA margins for 2026, benefiting from its diverse portfolio in specialty products and technologies.
5 Must-Read Analyst Questions From Envista's Q4 Earnings Call
Envista Holdings (NVST) reported stronger-than-anticipated Q4 results with significant revenue and profit growth, driven by new product launches and increased customer training. This article highlights five key analyst questions from the earnings call, covering topics such as 2026 guidance risks and upsides, drivers for Q4 growth, new product contributions to implant growth, Spark's profitability, and SG&A leverage and R&D investment. The company's future catalysts include new product commercial impact, Spark's operational efficiency, and developments in China's VBP policy.
Insider Selling: Envista (NYSE:NVST) SVP Sells 9,675 Shares of Stock
Envista Holdings Corporation's SVP, Mischa Reis, sold 9,675 shares of company stock for approximately $290,250 on February 10th, reducing their holdings by 23%. This insider sale comes as Envista's stock trades near its 52-week high with a high P/E ratio, despite strong Q4 earnings, positive guidance, and analyst upgrades. Investors are advised to consider this insider activity alongside the company's performance and valuation.
Mizuho raises Envista Holdings stock price target to $27 on strong outlook
Mizuho has increased its price target for Envista Holdings Corp. (NYSE:NVST) to $27.00 from $24.00, maintaining a Neutral rating, following the company's better-than-expected 2026 guidance. Envista's stock is currently trading near its 52-week high, boasting a 35.24% year-to-date return. The revised target is based on an increased 2026 and 2027 EPS forecast, with Mizuho anticipating Envista will outgrow the dental market.
Mizuho raises Envista Holdings stock price target to $27 on strong outlook
Mizuho has increased its price target for Envista Holdings Corp. to $27 from $24, maintaining a Neutral rating, following the company's strong 2026 guidance that met or exceeded medium-term targets. Envista is also expected to outgrow the dental market in 2026 and has seen upward revisions in its 2026 and 2027 EPS estimates, despite its current high P/E ratio. The stock is considered slightly undervalued by InvestingPro's Fair Value assessment.
Surging Earnings Estimates Signal Upside for Envista (NVST) Stock
Envista (NVST) is showing a strong earnings outlook, with analysts consistently raising their estimates for the dental products maker, leading to a Zacks Rank #1 (Strong Buy). This optimistic trend in earnings estimate revisions typically correlates with near-term stock price movements, and Envista has already seen a 23.2% increase in its stock over the past four weeks. The company is projected to achieve significant year-over-year earnings growth for both the current quarter and the full year, indicating potential for continued upside.
Envista Holdings Corp (NYSE:NVST) Q4 2025 Earnings Call Transcript
Envista Holdings Corp (NYSE:NVST) reported strong Q4 and full-year 2025 results, with core growth, EBITDA, and EPS exceeding medium-term objectives from their value creation plan. The company achieved widespread growth across all businesses, improved operational efficiency, and significantly increased shareholder returns through a share repurchase program. For 2026, Envista projects continued progress with core revenue growth of 2% to 4% and enhanced profitability, while acknowledging potential market volatility and specific VBP impacts in China.
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Envista Holdings (NVST)
The article highlights bullish sentiments from financial analysts on three healthcare stocks: Cigna (CI), Envista Holdings (NVST), and Arrowhead Pharmaceuticals (ARWR). Cigna received a Buy rating from Guggenheim and RBC Capital with price targets suggesting an 18.8% upside. Envista Holdings was reiterated a Buy by Bank of America Securities and upgraded to Buy by Leerink Partners, with a moderate buy consensus. Arrowhead Pharmaceuticals also maintained a Buy rating from RBC Capital and B. Riley Securities, projecting a significant upside.
Envista (NVST) Climbs 23% on Swing to Profit
Envista Holdings Corp. (NYSE:NVST) saw its stock climb by 23.4% to a nearly three-year high after reporting a significant swing to profitability. The company posted a $47 million net income in the last year, reversing a $1.1 billion net loss from 2024, with sales increasing by 8% to $2.7 billion. For the current year, Envista projects 2 to 4 percent core sales growth and a 7 to 13 percent increase in adjusted EBITDA.
Envista (NVST) Climbs 23% on Swing to Profit
Envista Holdings Corp. (NYSE:NVST) saw its stock climb 23.4% last week, reaching a nearly three-year high, after the company reported a swing to profitability in the previous year. The dental equipment company posted a net income of $47 million for last year, a significant improvement from a $1.1 billion net loss in 2024. Envista expects core sales to grow by 2 to 4 percent and adjusted EBITDA to increase by 7 to 13 percent for the current year.
William Blair upgrades Envista Holdings stock rating to Outperform By Investing.com
William Blair has upgraded Envista Holdings Corp. (NYSE:NVST) from Market Perform to Outperform due to strong quarterly results that surpassed expectations in sales and EPS. The dental products company, currently trading near its 52-week high, shows exceptional financial strength with a perfect Piotroski Score of 9. Despite a high P/E ratio, William Blair anticipates continued momentum driven by investments in implants and new product launches, projecting potential upside from EPS growth.
William Blair upgrades Envista Holdings stock rating to Outperform By Investing.com
William Blair has upgraded Envista Holdings (NYSE:NVST) from Market Perform to Outperform, citing strong quarterly results that exceeded expectations and a belief that the company's projected mid-single-digit growth and double-digit EPS growth in 2026 justify a premium valuation. Despite a high P/E ratio, InvestingPro analysis suggests the stock may be undervalued, with key growth drivers identified in implants and new product launches. The upgrade follows Envista's impressive Q4 2025 earnings and optimistic 2026 guidance, though Needham maintained a Hold rating.
Piper Sandler raises Envista Holdings stock price target to $25 on strong Q4
Piper Sandler has increased its price target for Envista Holdings Corp. to $25 from $21, maintaining a neutral rating, following the company's strong fourth-quarter performance with revenues and adjusted EPS exceeding Wall Street expectations. While the stock has already surpassed this new target, trading near its 52-week high, Piper Sandler expressed some reservation about the 2026 guidance, noting that the valuation appears full and future performance will likely depend on broader, albeit sluggish, dental market conditions. William Blair upgraded Envista to Outperform, citing strong results that even after adjusting for temporary benefits, remained significantly above consensus.
NVST Q4 Deep Dive: Broad-Based Growth and Margins Lift Outlook for 2026
Envista Holdings (NVST) reported strong Q4 CY2025 results, exceeding revenue and profit expectations with sales up 15% year-on-year to $750.6 million and adjusted EPS of $0.38, beating analyst consensus. The company's performance was driven by broad-based growth across all business units, new product launches, expanded clinical training, and operational improvements, including reduced general and administrative expenses. Envista's outlook for 2026 is positive, with guidance for sustained investment in R&D, new product innovation, and continued focus on profitability, despite potential macroeconomic volatility and uncertainties in the China market.
Envista Holdings stock hits 52-week high at $27.72
Envista Holdings (NVST) stock has reached a new 52-week high of $27.72, marking a 95% increase from its 52-week low. This surge is attributed to investor confidence, strategic initiatives, robust financial health, and strong fourth-quarter 2025 financial results that surpassed analyst expectations. While William Blair upgraded its rating to Outperform, Needham maintained a Hold rating despite the positive performance.
Why Envista (NVST) Stock Is Trading Up Today
Shares of Envista Holdings (NVST) jumped 13.5% after the company reported better-than-expected fourth-quarter financial results, with both revenue and adjusted earnings surpassing Wall Street estimates. The dental products maker also provided an optimistic full-year earnings outlook that exceeded projections, contributing to investor confidence. The stock saw a new 52-week high, up 31.6% since the beginning of the year.
Piper Sandler raises Envista Holdings stock price target to $25 on strong Q4
Piper Sandler has increased its price target for Envista Holdings Corp. (NYSE:NVST) to $25.00 from $21.00, maintaining a neutral rating, following the dental products company's strong fourth-quarter performance. Envista's revenue and adjusted EPS significantly surpassed Wall Street expectations, driven by double-digit growth in both segments. Despite the stock already trading above the new target, Piper Sandler expressed some reservation about the company's 2026 guidance, noting a "sluggish but stable" dental market.
Needham maintains Hold rating on Envista stock despite strong Q4 results
Needham has reiterated its Hold rating on Envista Holdings Corp. (NYSE:NVST) despite the company reporting strong fourth-quarter 2025 financial results that exceeded analyst expectations. The company showed financial strength with a high P/E ratio, strong revenue growth, and positive guidance for 2026. However, Needham believes the near-term upside is already priced in due to a significant increase in share price during after-hours trading.
William Blair upgrades Envista Holdings stock rating to Outperform
William Blair has upgraded Envista Holdings Corp. (NYSE:NVST) from Market Perform to Outperform following strong quarterly results that exceeded market expectations and a perfect Piotroski Score of 9. The firm projects mid-single-digit growth and double-digit EPS growth in 2026, driven by investments in implants and new product launches, despite previous valuation concerns. Envista’s recent financial performance and positive outlook led to the upgrade, with expectations for continued momentum and potential upside.
Envista: Q4 Earnings Snapshot
Envista Holdings Corp. (NVST) reported strong fourth-quarter earnings, surpassing Wall Street expectations with a profit of 38 cents per share, adjusted for special costs, and revenue of $750.6 million. For the full year, the company had a profit of 28 cents per share on revenue of $2.72 billion. Envista also provided a positive outlook, forecasting full-year earnings in the range of $1.35 to $1.45 per share.
Envista (NVST) Tops Q4 Earnings and Revenue Estimates
Envista (NVST) exceeded Q4 earnings and revenue estimates, reporting $0.38 per share against an expected $0.32, and revenues of $750.6 million, surpassing the consensus by 11.16%. The company has consistently beaten EPS and revenue estimates over the past four quarters. Envista currently holds a Zacks Rank #2 (Buy), indicating potential outperformance in the near future, although the Medical - Products industry outlook is in the bottom 29%.
Earnings call transcript: Envista Holdings Q4 2025 beats expectations
Envista Holdings (NVST) reported strong Q4 2025 results, exceeding analyst expectations with an EPS of $0.38 and revenues of $751 million. The company's core sales grew by 10.8%, driven by new product introductions and increased clinical training. Envista provided a positive outlook for 2026, projecting core sales growth of 2-4% and adjusted EPS between $1.35 and $1.45, underpinned by a solid value creation plan and continued investment in R&D.
Envista: Q4 Earnings Snapshot
Envista Holdings Corp. reported strong financial results for the fourth quarter, with net income of $32.9 million and adjusted earnings of 38 cents per share, surpassing Wall Street expectations. The company also exceeded revenue forecasts, posting $750.6 million for the quarter, and provided an outlook for full-year earnings between $1.35 and $1.45 per share.
Envista: Fourth Quarter Earnings Overview
Envista Holdings Corp. reported strong fourth-quarter results, with a net income of $32.9 million ($0.20 per share) and adjusted earnings of $0.38 per share, surpassing analyst expectations. The dental products manufacturer generated $750.6 million in revenue for the quarter, also exceeding estimates. For the full year, Envista reported $47 million in profit and $2.72 billion in revenue, projecting full-year earnings between $1.35 and $1.45 per share.
Envista Holdings soars after beating Q4 estimates, issues strong guidance
Envista Holdings Corporation (NYSE:NVST) surpassed Q4 analyst expectations with adjusted EPS of $0.38 and revenue of $751 million, leading to an 11.6% jump in after-hours trading. The dental products company also provided strong guidance for fiscal year 2026, projecting adjusted EPS of $1.35 to $1.45. This strong performance was attributed to growth across all major businesses and geographical regions, alongside significant share repurchases.
Envista (NYSE:NVST) Beats Expectations in Strong Q4 CY2025
Envista Holdings (NYSE:NVST) significantly surpassed Wall Street's expectations in Q4 CY2025, reporting a 15% year-on-year revenue increase to $750.6 million and a non-GAAP profit of $0.38 per share, beating estimates by 17.7%. The company also provided strong adjusted EPS guidance for CY2026, exceeding analyst projections. While long-term revenue growth has been moderate, and operating margins have historically struggled, the latest quarter shows promising improvements in profitability and efficiency, leading to a positive market reaction.
Homestead Advisers Corp Sells 71,400 Shares of Envista Holdings Corporation $NVST
Homestead Advisers Corp has reduced its stake in Envista Holdings Corporation ($NVST) by selling 71,400 shares, decreasing its total holdings to 223,000 shares valued at approximately $4.543 million. Other institutional investors like Optimize Financial, Hantz Financial Services, Allianz Asset Management, Convergence Investment Partners, and Keybank National Association OH have either purchased new stakes or increased their existing holdings in Envista. Analyst ratings for Envista are mixed, with a consensus "Hold" rating and an average price target of $22.75, despite some firms raising their targets to $25-$27, while Weiss Ratings reaffirmed a "Sell" rating.
Envista lifts profit, returns $166M to investors and maps 2026 goals
Envista Holdings Corporation reported strong Q4 and full-year 2025 results, with significant core sales and adjusted EBITDA growth, largely driven by strategic focus on growth, operations, and people. The company also returned $166 million to shareholders through share repurchases and provided optimistic 2026 guidance, projecting continued growth in core sales, adjusted EBITDA, and EPS, along with 100% free cash conversion. Despite a decline in operating and free cash flow in Q4 and FY 2025 compared to 2024, the market reacted positively to the news.
Envista (NVST) To Report Earnings Tomorrow: Here Is What To Expect
Envista Holdings (NVST) is set to report earnings, with analysts expecting revenue growth of 4% year-on-year to $678.7 million and adjusted earnings of $0.32 per share. The company has a history of beating revenue expectations but has also missed Wall Street's estimates twice in the last two years. While the healthcare equipment segment has seen minor stock price declines, Envista's shares are up 1.6% in the last month.
Envista Holdings (NVST) Valuation Check After Recent Share Price Gains And Longer Term Return Slowdown
Envista Holdings (NVST) recently closed at $23.84, showing an 8.36% increase over the past month and 17.09% over three months, despite a longer-term slowdown in shareholder returns. The company is currently estimated to be 11.7% undervalued with a fair value of $27.00 per share, driven by improved net profit margins and a more conservative P/E multiple. However, the narrative acknowledges challenges like pressure on traditional dental products and tighter pricing.
Massachusetts Financial Services Co. MA Buys 523,949 Shares of Envista Holdings Corporation $NVST
Massachusetts Financial Services Co. MA significantly increased its stake in Envista Holdings Corporation (NYSE:NVST) by 22.0% in Q3, purchasing 523,949 additional shares. This brings their total holdings to 2,905,149 shares, valued at approximately $59.18 million. Despite this increase, analysts maintain a "Hold" rating on Envista with a consensus price target of $22.15, while the company reported an EPS beat and 11.5% revenue growth.
Mizuho Upgrades Envista Holdings (NVST)
Mizuho has upgraded Envista Holdings (NVST) from Underperform to Neutral. Despite the upgrade, the average one-year price target suggests a 9.54% downside from its current closing price, with institutional ownership decreasing in the last quarter.
Mizuho upgrades Envista Holdings stock rating to Neutral on growth outlook
Mizuho has upgraded Envista Holdings Corp. (NYSE:NVST) from Underperform to Neutral, raising its price target to $24.00 from $19.00 due to "greater visibility on faster earnings growth." Envista's stock is currently trading above this new target, and the dental products company is expected to see net income growth this year despite a high P/E ratio. This upgrade follows a strong Q3 2025 earnings report that surpassed analyst expectations.
Mizuho upgrades Envista Holdings stock rating to Neutral on growth outlook
Mizuho has upgraded Envista Holdings Corp. (NYSE:NVST) from Underperform to Neutral, raising its price target to $24.00 from $19.00, citing greater visibility on faster earnings growth for the dental products company. This upgrade follows Envista's stronger-than-expected Q3 2025 earnings and revenue, with analysts like Evercore ISI and Stifel also maintaining positive ratings on the stock. Despite a high current P/E ratio, net income is anticipated to grow this year.
Envista Holdings Corp stock hits 52-week high at $23.97 By Investing.com
Envista Holdings Corp (NVST) stock reached a new 52-week high of $23.97, reflecting strong investor confidence and a 24.5% appreciation over the past year. The dental products company boasts a perfect Piotroski Score of 9 and comfortable liquidity, with its next earnings report due in 22 days. Recent third-quarter results showed the company exceeding EPS and revenue estimates, leading to analyst price target adjustments and maintained positive ratings.
Envista Holdings Corp stock hits 52-week high at $23.97
Envista Holdings Corp (NVST) stock reached a new 52-week high of $23.97, reflecting strong investor confidence and a 24.5% appreciation over the last year. The company boasts a perfect Piotroski Score of 9 and a robust financial position, with liquid assets comfortably exceeding short-term obligations. Analysts maintain positive outlooks, and its next earnings report is anticipated on February 5th.
Envista Holdings Corp stock hits 52-week high at $23.97 By Investing.com
Envista Holdings Corp (NVST) has reached a new 52-week high of $23.97, indicating strong investor confidence and a 24.5% appreciation over the past year. The dental products company boasts a Piotroski Score of 9 and robust financial health, with its liquid assets exceeding short-term obligations. Analysts maintain a positive outlook, with some reiterating "Buy" or "Outperform" ratings, suggesting the stock is currently undervalued ahead of its next earnings report on February 5.
Envista Schedules Fourth Quarter 2025 Earnings Call
Envista Holdings Corporation (NYSE: NVST) announced it will report financial results for its fourth quarter 2025 on Thursday, February 5, 2026. The company will host a conference call and webcast on the same day at 2:00 PM PT to discuss these results. The webcast and related materials will be available on Envista's investor relations website.
Envista to Present at the 44th Annual J.P. Morgan Healthcare Conference
Envista Holdings Corporation (NYSE: NVST) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, from 3:45 – 4:25 pm PST. A live audio webcast and replay will be available in the Investors section of Envista's website. Envista is a global dental industry leader with over 30 brands dedicated to improving patients' lives.
Envista to Present at the 44th Annual J.P. Morgan Healthcare Conference
Envista Holdings Corporation (NYSE: NVST) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. A live audio webcast will be available on the Investors section of Envista's website, with a replay accessible for 30 days. Envista is a global leader in the dental industry, known for unifying over 30 brands and innovating in dental care technologies.
Envista Holdings Corp stock hits 52-week high at 22.75 USD
Envista Holdings Corp (NVST) has reached a new 52-week high of $22.75, showing strong investor confidence and a 16.06% increase over the past year. The company boasts a perfect Piotroski Score of 9 and a healthy current ratio of 2.37, indicating strong financial health and liquidity. Despite recent gains, analysis suggests the stock may still be undervalued, supported by a 7% free cash flow yield and a "GOOD" financial health rating.
Envista Holdings Corp stock hits 52-week high at 22.75 USD By Investing.com
Envista Holdings Corp (NVST) recently reached a 52-week high of $22.75, showcasing strong financial health with a perfect Piotroski Score of 9 and significant market confidence through a 16.06% 1-year change. The company also reported robust Q3 2025 earnings, surpassing EPS and revenue expectations. Despite recent gains, InvestingPro suggests the stock may still be undervalued, indicating further growth potential.
Envista Holdings Corp stock hits 52-week high at 22.75 USD
Envista Holdings Corp. (NVST) recently achieved a new 52-week high of $22.75, reflecting strong investor confidence and a 16.06% increase over the past year. Despite this growth, InvestingPro analysis suggests the stock may still be undervalued, boasting a perfect Piotroski Score of 9 and high free cash flow yield. The company also reported robust Q3 2025 financial results, with EPS and revenue exceeding expectations, supported by positive analyst outlooks.
Envista Holdings Corp stock hits 52-week high at 22.75 USD
Envista Holdings Corp (NVST) recently reached a 52-week high of $22.75, reflecting strong financial performance and investor confidence. The company boasts a Piotroski Score of 9, a healthy current ratio of 2.37, and a 1-year stock change of 16.06%. Despite recent gains, InvestingPro analysis suggests the stock may be undervalued, with promising fundamentals like a 7% free cash flow yield and a "GOOD" financial health rating.
Pacer Advisors Inc. Sells 768,984 Shares of Envista Holdings Corporation $NVST
Pacer Advisors Inc. significantly reduced its stake in Envista Holdings Corporation (NYSE:NVST), selling 768,984 shares and retaining only 39,271 shares valued at approximately $800,000. Despite this reduction, Envista's stock opened at $21.70, and the company recently beat Q3 earnings expectations with an EPS of $0.32 and revenue of $669.9 million. The stock currently holds a consensus "Hold" rating from analysts with an average target price of $21.77.
Dental Equipment & Technology Q3 Earnings: Envista (NYSE:NVST) Simply the Best
Envista Holdings (NYSE:NVST) delivered the strongest Q3 performance among tracked dental equipment and technology stocks, beating analyst revenue estimates significantly and achieving the fastest revenue growth. Henry Schein (NYSE:HSIC) and Align Technology (NYSE:ALGN) also reported strong quarters, with their stocks rising after earnings. Dentsply Sirona (NYSE:XRAY), however, had the weakest performance with declining revenues and missed EPS guidance.
Dental Equipment & Technology Q3 Earnings: Envista (NYSE:NVST) Simply the Best
Envista Holdings (NYSE:NVST) led the dental equipment and technology sector in Q3 earnings, significantly beating analyst revenue estimates with an 11.5% year-over-year increase. The report highlights strong performance across the industry, with companies like Henry Schein and Align Technology also exceeding expectations, while Dentsply Sirona reported weaker results. The sector benefits from digital innovation but faces challenges from economic uncertainty and regulatory pressures.
Envista (NYSE:NVST) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Envista (NYSE:NVST) from a "strong-buy" to a "buy" rating, though the overall analyst consensus remains a "Hold" with an average price target of $21.77. Despite Envista beating Q3 earnings and revenue estimates, the stock is trading around $22 with a high P/E ratio of 247.47. Several other analysts have also provided varying ratings and price targets for the company recently.
Envista (NVST) Valuation Check After Recent Share Price Gains
Envista Holdings (NVST) has seen solid share price gains recently, driven by improving earnings and steady dental equipment demand. While Simply Wall St's narrative pegs the stock as about right in value at $22.15, their DCF model suggests a modest 2.5% undervaluation. Investors should consider potential risks like Chinese pricing reforms, but the company's cost reductions and operational optimizations forecast continued margin improvement.
